Related Experiment Video

Updated: Oct 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol]

A J Scheen1

  • 1Département de Médecine, Université de Liège.

Revue Medicale De Liege
|February 3, 1999
PubMed

Insights

Treating low HDL cholesterol involves assessing cardiovascular risk and lipid profile. Lifestyle changes are primary, with fibrates or nicotinic acid considered for associated hypertriglyceridemia, though isolated low HDL cholesterol is challenging to treat.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Preventive Medicine

Context:

  • Low high-density lipoprotein (HDL) cholesterol is a significant cardiovascular risk factor.
  • Treatment decisions are guided by the patient's overall cardiovascular risk and specific lipid profile abnormalities.
  • Therapeutic strategies must differentiate between isolated low HDL, associated hypertriglyceridemia, and combined elevations of low-density lipoprotein (LDL) cholesterol.

Purpose:

  • To outline the strategic approach for managing individuals with low HDL cholesterol.
  • To emphasize the importance of lifestyle modifications as the first line of treatment.
  • To review pharmacological options and their efficacy based on lipid profile characteristics.

Summary:

  • Management of low HDL cholesterol necessitates a comprehensive cardiovascular risk assessment.
  • Lifestyle interventions, including diet and exercise, are paramount and often effective, particularly when low HDL is linked with hypertriglyceridemia.
  • Pharmacological treatments like fibrates or nicotinic acid show promise for associated hypertriglyceridemia, but yield less favorable outcomes for isolated low HDL cholesterol.

Impact:

  • Provides a clear framework for clinicians managing dyslipidemia.
  • Highlights the primary role of lifestyle modifications in improving HDL cholesterol levels.
  • Informs therapeutic choices, optimizing treatment based on individual patient lipid profiles and associated conditions.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...